全文获取类型
收费全文 | 799篇 |
免费 | 17篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 25篇 |
妇产科学 | 8篇 |
基础医学 | 38篇 |
口腔科学 | 4篇 |
临床医学 | 244篇 |
内科学 | 217篇 |
皮肤病学 | 20篇 |
神经病学 | 12篇 |
特种医学 | 11篇 |
外科学 | 58篇 |
综合类 | 42篇 |
一般理论 | 1篇 |
预防医学 | 100篇 |
药学 | 39篇 |
中国医学 | 1篇 |
肿瘤学 | 18篇 |
出版年
2017年 | 5篇 |
2015年 | 34篇 |
2014年 | 26篇 |
2013年 | 18篇 |
2012年 | 37篇 |
2011年 | 39篇 |
2010年 | 34篇 |
2009年 | 55篇 |
2008年 | 30篇 |
2007年 | 40篇 |
2006年 | 56篇 |
2005年 | 28篇 |
2004年 | 23篇 |
2003年 | 8篇 |
2002年 | 13篇 |
2001年 | 37篇 |
2000年 | 14篇 |
1999年 | 32篇 |
1998年 | 38篇 |
1997年 | 20篇 |
1996年 | 31篇 |
1995年 | 31篇 |
1994年 | 27篇 |
1993年 | 16篇 |
1992年 | 8篇 |
1991年 | 8篇 |
1990年 | 10篇 |
1989年 | 8篇 |
1988年 | 5篇 |
1987年 | 8篇 |
1986年 | 12篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1983年 | 3篇 |
1982年 | 3篇 |
1981年 | 3篇 |
1978年 | 3篇 |
1966年 | 2篇 |
1965年 | 2篇 |
1961年 | 2篇 |
1960年 | 4篇 |
1959年 | 12篇 |
1958年 | 2篇 |
1957年 | 4篇 |
1956年 | 3篇 |
1954年 | 2篇 |
1947年 | 2篇 |
1941年 | 2篇 |
1937年 | 3篇 |
1936年 | 2篇 |
排序方式: 共有840条查询结果,搜索用时 140 毫秒
41.
42.
43.
44.
M. PIHUSCH A. BACIGALUPO† J. SZER‡ M. VON DEPKA PRONDZINSKI§ B. GASPAR-BLAUDSCHUN¶ L. HYVELED¶ B. BRENNER FOR THE FBMT- TRIAL INVESTIGATORS 《Journal of thrombosis and haemostasis》2005,3(9):1935-1944
BACKGROUND: Bleeding is a common complication following hematopoietic stem cell transplantation (HSCT) and standard hemostatic treatment is often ineffective. We conducted a multicentre, randomized trial of the efficacy and safety of activated recombinant factor VII (rFVIIa, NovoSeven) in the treatment of bleeding following HSCT. METHODS: 100 patients with moderate or severe bleeding (52 gastrointestinal; 26 hemorrhagic cystitis; seven pulmonary; one cerebral; 14 other) were included from days +2 to +180 post-transplant (97 allogeneic; three autologous) to receive seven doses of rFVIIa (40, 80 or 160 microg kg(-1)) or placebo every 6 h. The primary efficacy endpoint was the change in bleeding score between the first administration and 38 h. RESULTS: No significant effect of increasing rFVIIa dose was observed on the primary endpoint. A post hoc analysis comparing each rFVIIa dose with placebo showed that 80 microg kg(-1) rFVIIa improved the bleeding score at the 38 h time point (81% vs. 57%, P = 0.021). This effect was not seen at 160 microg kg(-1). There were no differences in transfusion requirements across dose groups. There was no trend in the type or number of severe adverse events observed. Six thromboembolic events were observed in the active treatment groups: three during, and three following the 96-h observation period. CONCLUSIONS: Despite no overall effect of rFVIIa treatment on primary endpoint, post hoc analysis showed an improvement in the control of bleeding for 80 microg kg(-1) rFVIIa vs. standard hemostatic treatment. The heterogeneity of the population may have contributed to the lack of an increasing effect with increased dose. Further trials should focus upon identifying the patient populations that may benefit from treatment with rFVIIa. 相似文献
45.
林泽娴 《湖北民族学院学报(医学版 )》1986,(1)
本文分析了连续硬膜外麻醉术用于女性尿漏手术85例的情况。提出术前、术中应注意的问题及其某些处理方法。并认为此种麻醉术用于女性尿漏手术,不失为是一种安全、可靠、易于掌握的麻醉方法。 相似文献
46.
47.
GREGG W. STONE M.D. BRUCE R. BRODIE M.D. JOHN J. GRIFFIN M.D. † MARIE CLAUDE MORICE M.D. ‡ COSTANTINO COSTANTINI M.D. § PAUL A. OVERLIE M.D. THOMAS J. LINNEMEIER M.D. ¶ JEFFREY MOSES M.D. # WILLIAM W. O'NEILL M.D. CINDY L. GRINES M.D. ON BEHALF OF THE PRIMARY ANGIOPLASTY IN MYOCARDIAL INFARCTION INVESTIGATORS 《Journal of interventional cardiology》1999,12(2):101-108
To study the additive benefits of routine stent implantation in patients undergoing primary percutaneous transluminal coronary angioplasty (PTCA) at experienced centers, we compared the outcomes of the 982 patients undergoing PTCA for acute myocardial infarction (AMI) in the Primary Angioplasty in Myocardial Infarction-2 (PAMI-2) trial (only 1% of whom were stented) to the 312 patients in the PAMI Stent Pilot Trial (236 [76%] of whom were stented). The inclusion and exclusion criteria, PTCA methodology, and definitions used were prespecified to be identical between the two trials. Compared to the primary PTCA approach in PAMI-2, the strategy of stenting all eligible lesions in the PAMI Stent Pilot Trial was associated with reduced rates of in-hospital death (0.6% vs 2.7%, P = 0.03), reinfarction (1.3% vs 4.6%, P = 0.008), recurrent ischemia (3.5% vs 11.6%, P < 0.0001), target vessel revascularization (7.3% vs 11.4%, P = 0.04), and a shorter hospital stay (6.4 ± 4.4 vs 7.1 ± 6.2 days, P = 0.01). By multiple logistic regression analysis in 1,294 patients, stent implantation versus PTCA only was the strongest predictor of freedom from the composite in-hospital end point of death, reinfarction, or target vessel revascularization (TVR) (8.3% vs 15.0%, multivariate odds ratio = 0.4, P < 0.0001). These data strongly suggest that despite the excellent results achieved when primary PTCA is performed by experienced operators, the short-term outcomes of mechanical reperfusion can be further improved by a primary stent strategy. 相似文献
48.
L. POLLER M. KEOWN S. IBRAHIM A. M. H. P. VAN DEN BESSELAAR† C. ROBERTS‡ K. STEVENSON§ A. TRIPODI¶ A. PATTISON J. JESPERSEN†† ON BEHALF OF EUROPEAN CONCERTED ACTION ON ANTICOAGULATION 《Journal of thrombosis and haemostasis》2007,5(5):1002-1009
BACKGROUND: It is no longer feasible to check local International Normalized Ratios (INR) by the World Health Organization International Sensitivity Index (ISI) calibrations because the necessary manual prothrombin time technique required has generally been discarded. OBJECTIVES: An international collaborative study at 77 centers has compared local INR correction using the two alternative methods recommended in the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis guidelines: local ISI calibration and 'Direct INR'. METHODS: Success of INR correction by local ISI calibration and with Direct INR was assessed with a set of 27 certified lyophilized plasmas (20 from patients on warfarin and seven from normals). RESULTS: At 49 centers using human thromboplastins, 3.0% initial average local INR deviation from certified INR was reduced by local ISI calibration to 0.7%, and at 25 centers using rabbit reagents, from 15.9% to 7.5%. With a minority of commercial thromboplastins, mainly 'combined' rabbit reagents, INR correction was not achieved by local ISI calibration. However, when rabbit combined reagents were excluded the overall mean INR deviation after correction was reduced further to 3.9%. In contrast, with Direct INR, mean deviation using human thromboplastins increased from 3.0% to 6.6%, but there was some reduction with rabbit reagents from 15.9% to 10% (12.3% with combined reagents excluded). CONCLUSIONS: Local ISI calibration gave INR correction for the majority of PT systems but failed at the small number using combined rabbit reagents suggesting a need for a combined reference thromboplastin. Direct INR correction was disappointing but better than local ISI calibration with combined rabbit reagents. Interlaboratory variability was improved by both procedures with human reagents only. 相似文献
49.